Alliance for Regenerative Medicine (ARM) Neuralstem Presentation

Alliance for Regenerative Medicine (ARM) Neuralstem Presentation
April 17, 2018
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. The company’s lead asset and stem cell therapy candidate, NSI-566, is a spinal cord-derived neural stem cell line being tested in Amyotrophic Lateral Sclerosis (ALS), chronic spinal cord injury (cSCI) and ischemic stroke. Additionally, NSI-189, is a chemical entity in development for major depressive disorder (MDD) and for Angelman syndrome, irradiation-induced cognitive impairment, neuropathy associated with Type 1 and Type 2 diabetes and stroke. These product candidates are based on the company’s proprietary neural stem cell technology. http://www.neuralstem.com

Karl Johe, Ph.D., Chief Scientific Officer
Germantown, MD
(NASDAQ: CUR)

This entry was posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research, Stem Cell Research and tagged , . Bookmark the permalink.